Comparative Pharmacology
Head-to-head clinical analysis: NEO CORTEF versus NEO MEDROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEO CORTEF versus NEO MEDROL.
NEO-CORTEF vs NEO-MEDROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis. Hydrocortisone is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to suppress inflammation and immune response.
Neo-Medrol is a combination of neomycin (an aminoglycoside antibiotic) and methylprednisolone (a corticosteroid). Neomycin inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, while methylprednisolone suppresses inflammation by binding to glucocorticoid receptors, modulating gene expression, and inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
Apply a thin layer to the affected area 3 to 4 times daily. Use the 0.5% strength for mild conditions and 1% for more severe conditions.
Initial dose: 4-48 mg orally per day, divided into 1-4 doses, depending on severity. Intravenous or intramuscular: 10-500 mg/day as methylprednisolone sodium succinate, given as single or divided doses. Intra-articular or soft tissue injection: 4-80 mg as methylprednisolone acetate, depending on joint size.
None Documented
None Documented
Terminal half-life 2-4 hours for neomycin; hydrocortisone half-life 1-2 hours. Clinical context: q6-8h dosing.
Plasma terminal half-life: 2-4 hours (methylprednisolone); clinical effect half-life ~18-36 hours due to receptor occupancy.
Renal (70-80% as free drug and metabolites), fecal (20-30% via bile).
Renal (primarily as inactive metabolites); <5% unchanged. Biliary/fecal excretion minimal.
Category C
Category C
Corticosteroid with Antibiotic
Corticosteroid with Antibiotic